New Copycat Bolus Insulin
New Copycat Bolus Insulin
The Food and Drug Administration (FDA) has approved Admelog (Sanofi-Adventis US), the first copycat version of short-acting insulin lispro (Humalog, Eli Lilly) to treat individuals aged 3 years and older with type 1 diabetes and adults with type 2 diabetes.
Download our FREE Updated Insulin PocketCard
Features:
Approved for use as an injection, via pump, or intravenously.
It will be available both in vials and as a prefilled pen (Admelog SoloStar).
The FDA approved Admelog through an abbreviated approval pathway under which companies can rely on the FDA’s previous approval of a drug as safe and effective or on previously published literature supporting safety and/or effectiveness. This process is meant to reduce drug development costs in order to reduce the drug’s price on the market.
Medication Update Webinar – Feb 19, 2018 11:30 to 1pm (PST)
Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.
Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?
We are here to help out!
This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers.
If you want cutting edge information on the latest pharmacology, we highly recommend this Meds Update.
To Join Us and earn CEs you have 2 options:
![](/wp-content/uploads/2023/01/insta-png-v5.png")
